These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28830537)

  • 1. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.
    Lang L; Shay C; Zhao X; Teng Y
    J Exp Clin Cancer Res; 2017 Aug; 36(1):112. PubMed ID: 28830537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
    Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
    Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
    Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
    J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling.
    Davis JE; Xie X; Guo J; Huang W; Chu WM; Huang S; Teng Y; Wu G
    Oncotarget; 2016 Jun; 7(26):39834-39845. PubMed ID: 27213581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission.
    Hu HF; Xu WW; Li YJ; He Y; Zhang WX; Liao L; Zhang QH; Han L; Yin XF; Zhao XX; Pan YL; Li B; He QY
    Theranostics; 2021; 11(4):1828-1844. PubMed ID: 33408784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
    Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
    Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.
    Goldshmit Y; Trangle SS; Kloog Y; Pinkas-Kramarski R
    Oncotarget; 2014 Sep; 5(18):8602-13. PubMed ID: 25261371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apigenin blocks IKKα activation and suppresses prostate cancer progression.
    Shukla S; Kanwal R; Shankar E; Datt M; Chance MR; Fu P; MacLennan GT; Gupta S
    Oncotarget; 2015 Oct; 6(31):31216-32. PubMed ID: 26435478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
    Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
    Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
    Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
    Xie X; Tang SC; Cai Y; Pi W; Deng L; Wu G; Chavanieu A; Teng Y
    Oncotarget; 2016 Sep; 7(36):58111-58120. PubMed ID: 27517156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
    Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
    Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
    Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models.
    Badr G; Al-Sadoon MK; Rabah DM
    Free Radic Biol Med; 2013 Dec; 65():175-189. PubMed ID: 23811005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrandrine suppresses proliferation, induces apoptosis, and inhibits migration and invasion in human prostate cancer cells.
    Liu W; Kou B; Ma ZK; Tang XS; Lv C; Ye M; Chen JQ; Li L; Wang XY; He DL
    Asian J Androl; 2015; 17(5):850-3. PubMed ID: 25677131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.